Among the various mechanisms mediating drug resistance to CDK4/6 inhibitors found in HR‐positive/HER2‐negative breast cancer cells, upregulation of the PI3K/mTOR pathway is a very common one, making it a potential target for reversal of drug resistance [12]. Here, ERBB2 is linked to breast carcinoma.